Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Prevention, treatment and cure of HIV infection

Nature Reviews Microbiology volume 21, pages 657–670 (2023)Cite this article

Subjects

Abstract

The development of antiretroviral therapy for the prevention and treatment of HIV infection has been marked by a series of remarkable successes. However, the efforts to develop a vaccine have largely failed, and efforts to discover a cure are only now beginning to gain traction. In this Review, we describe recent progress on all fronts — pre-exposure prophylaxis, vaccines, treatment and cure — and we discuss the unmet needs, both current and in the coming years. We describe the emerging arsenal of drugs, biologics and strategies that will hopefully address these needs. Although HIV research has largely been siloed in the past, this is changing, as the emerging research agenda is marked by multiple cross-discipline synergies and collaborations. As the limitations of antiretroviral drugs as a means to truly end the epidemic are becoming more apparent, there is a great need for continued efforts to develop an effective preventative vaccine and a scalable cure, both of which remain formidable challenges.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Mechanism of action for current and emerging antiretroviral therapies.
Fig. 2: bNAbs vaccine strategies.
Fig. 3: Immunotherapy for HIV.
Fig. 4: Multiple roles of bNAbs in treatment and cure.
Fig. 5: HIV exposure and infection.

Similar content being viewed by others

References

  1. Landovitz, R. J. et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N. Engl. J. Med. 385, 595–608 (2021).

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Grant, R. M. et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363, 2587–2599 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Joint United Nations Programme on HIV/AIDS. Global HIV and AIDS statistics — 2022 fact sheet. UNAIDS https://www.unaids.org/en/resources/fact-sheet (2022).

  4. Cohen, S. E. et al. Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report. Lancet HIV https://doi.org/10.1016/S2352-3018(18)30288-1 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Cohen, S. M., Hu, X., Sweeney, P., Johnson, A. S. & Hall, H. I. HIV viral suppression among persons with varying levels of engagement in HIV medical care, 19 US jurisdictions. J. Acquir. Immune Defic. Syndr. 67, 519–527 (2014).

    PubMed  Google Scholar 

  6. Havlir, D. V. et al. HIV testing and treatment with the use of a community health approach in rural Africa. N. Engl. J. Med. 381, 219–229 (2019).

    PubMed  PubMed Central  Google Scholar 

  7. Hayes, R. J. et al. Effect of universal testing and treatment on HIV incidence — HPTN 071 (PopART). N. Engl. J. Med. 381, 207–218 (2019).

    PubMed  PubMed Central  Google Scholar 

  8. Makhema, J. et al. Universal testing, expanded treatment, and incidence of HIV infection in Botswana. N. Engl. J. Med. 381, 230–242 (2019).

    PubMed  PubMed Central  Google Scholar 

  9. Cohen, M. S. et al. Prevention of HIV-1 infection with early antiretroviral therapy. N. Engl. J. Med. 365, 493–505 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Larmarange, J. et al. The impact of population dynamics on the population HIV care cascade: results from the ANRS 12249 Treatment as Prevention trial in rural KwaZulu-Natal (South Africa). J. Int. AIDS Soc. 21, e25128 (2018).

    PubMed  PubMed Central  Google Scholar 

  11. Thigpen, M. C. et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N. Engl. J. Med. 367, 423–434 (2012).

    CAS  PubMed  Google Scholar 

  12. Liu, A. Y. et al. Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern. Med. 176, 75–84 (2016).

    PubMed  PubMed Central  Google Scholar 

  13. Choopanya, K. et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 381, 2083–2090 (2013).

    PubMed  Google Scholar 

  14. Mayer, K. H. et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet 396, 239–254 (2020).

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Molina, J. M. et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 Infection. N. Engl. J. Med. 373, 2237–2246 (2015).

    CAS  PubMed  Google Scholar 

  16. World Health Organization. Guidelines on Long-Acting Injectable Cabotegravir for HIV Prevention (WHO, 2022).

  17. Gandhi, R. T. et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA panel. J. Am. Med. Assoc. 329, 63–84 (2022).

    Google Scholar 

  18. Van Damme, L. et al. Preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 367, 411–422 (2012).

    PubMed  PubMed Central  Google Scholar 

  19. Marrazzo, J. M. et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 372, 509–518 (2015).

    PubMed  PubMed Central  Google Scholar 

  20. Abdool Karim, Q. et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329, 1168–1174 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Baeten, J. M. et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N. Engl. J. Med. 367, 399–410 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Baeten, J. M. et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N. Engl. J. Med. 375, 2121–2132 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  23. World Health Organization. WHO recommends the dapivirine vaginal ring as a new choice for HIV prevention for women at substantial risk of HIV infection. WHO https://www.who.int/news/item/26-01-2021-who-recommends-the-dapivirine-vaginal-ring-as-a-new-choice-for-hiv-prevention-for-women-at-substantial-risk-of-hiv-infection (2021).

  24. Baeten, J. M., Hendrix, C. W. & Hillier, S. L. Topical microbicides in HIV prevention: state of the promise. Annu. Rev. Med. 71, 361–377 (2020).

    CAS  PubMed  Google Scholar 

  25. Delany-Moretlwe, S. et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet 399, 1779–1789 (2022).

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Marzinke, M. A. et al. Characterization of human immunodeficiency virus (HIV) infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083. J. Infect. Dis. 224, 1581–1592 (2021).

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Gulick, R. M. et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337, 734–739 (1997).

    CAS  PubMed  Google Scholar 

  28. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Clinicalinfo.HIV.gov https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new (2023).

  29. Trickey, A. et al. Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study. Lancet HIV 9, e404–e413 (2022).

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Venter, W. D. F. et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N. Engl. J. Med. 381, 803–815 (2019).

    CAS  PubMed  Google Scholar 

  31. Editorial. PEPFAR looks to the future. Lancet HIV 9, e367 (2022).

    Google Scholar 

  32. Orkin, C. et al. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study. Lancet HIV 8, e185–e196 (2021).

    CAS  PubMed  Google Scholar 

  33. Christopoulos, K. A. et al. First demonstration project of long-acting injectable antiretroviral therapy for persons with and without detectable HIV viremia in an urban HIV clinic. Clin. Infect. Dis. 76, e645–e651 (2022).

    PubMed Central  Google Scholar 

  34. Segal-Maurer, S. et al. Capsid Inhibition with lenacapavir in multidrug-resistant HIV-1 infection. N. Engl. J. Med. 386, 1793–1803 (2022).

    CAS  PubMed  Google Scholar 

  35. Benhabbour, S. R. et al. Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery. Nat. Commun. 10, 4324 (2019).

    PubMed  PubMed Central  Google Scholar 

  36. Kovarova, M. et al. Ultra-long-acting removable drug delivery system for HIV treatment and prevention. Nat. Commun. 9, 4156 (2018).

    PubMed  PubMed Central  Google Scholar 

  37. Haynes, B. F., Burton, D. R. & Mascola, J. R. Multiple roles for HIV broadly neutralizing antibodies. Sci. Transl Med. 11, eaaz2686 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Caskey, M., Klein, F. & Nussenzweig, M. C. Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic. Nat. Med. 25, 547–553 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Gaudinski, M. R. et al. Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. Lancet HIV 6, e667–e679 (2019).

    PubMed  Google Scholar 

  40. Gaudinski, M. R. et al. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a phase 1 open-label clinical trial in healthy adults. PLoS Med. 15, e1002493 (2018).

    PubMed  PubMed Central  Google Scholar 

  41. Corey, L. et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N. Engl. J. Med. 384, 1003–1014 (2021).

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Sneller, M. C. et al. Combination anti-HIV antibodies provide sustained virological suppression. Nature 606, 375–381 (2022).

    CAS  PubMed  Google Scholar 

  43. Gaebler, C. et al. Prolonged viral suppression with anti-HIV-1 antibody therapy. Nature 606, 368–374 (2022).

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Pegu, A. et al. Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys. Cell Rep. 38, 110199 (2022).

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Collins, F. et al. The NIH-led research response to COVID-19. Science 379, 441–444 (2023).

    CAS  PubMed  Google Scholar 

  46. Buchbinder, S. P. et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372, 1881–1893 (2008).

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209–2220 (2009).

    CAS  PubMed  Google Scholar 

  48. Haynes, B. F. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275–1286 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Gray, G. E. et al. Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. Sci. Transl Med. 11, eaax1880 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Moodie, Z. et al. Analysis of the HVTN 702 Phase 2b-3 HIV-1 vaccine trial in South Africa assessing RV144 antibody and T-cell correlates of HIV-1 acquisition risk. J. Infect. Dis. 226, 246–257 (2022).

    CAS  PubMed  PubMed Central  Google Scholar 

  51. Gray, G. E. et al. Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120-MF59 in adults. N. Engl. J. Med. 384, 1089–1100 (2021).

    CAS  PubMed  PubMed Central  Google Scholar 

  52. Barouch, D. H. et al. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet 392, 232–243 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  53. Hansen, S. G. et al. Immune clearance of highly pathogenic SIV infection. Nature 502, 100–104 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Jiang, C. et al. Distinct viral reservoirs in individuals with spontaneous control of HIV-1. Nature 585, 261–267 (2020).

    CAS  PubMed  PubMed Central  Google Scholar 

  55. Turk, G. et al. A possible sterilizing cure of HIV-1 infection without stem cell transplantation. Ann. Intern. Med. 175, 95–100 (2022).

    PubMed  Google Scholar 

  56. Jardine, J. G. et al. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science 351, 1458–1463 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Haynes, B. F. et al. Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Nat. Rev. Immunol. 23, 142–158 (2023).

    CAS  PubMed  Google Scholar 

  58. Leggat, D. J. et al. Vaccination induces HIV broadly neutralizing antibody precursors in humans. Science 378, eadd6502 (2022).

    CAS  PubMed  Google Scholar 

  59. Sanders, R. W. et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 9, e1003618 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  60. Borst, A. J. et al. Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core. eLife 7, e37688 (2018).

    PubMed  PubMed Central  Google Scholar 

  61. Arunachalam, P. S. et al. T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers. Nat. Med. 26, 932–940 (2020).

    CAS  PubMed  PubMed Central  Google Scholar 

  62. McMahan, K. et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 590, 630–634 (2021).

    CAS  PubMed  Google Scholar 

  63. Ndung’u, T., McCune, J. M. & Deeks, S. G. Why and where an HIV cure is needed and how it might be achieved. Nature 576, 397–405 (2019).

    PubMed  PubMed Central  Google Scholar 

  64. Deeks, S. G. et al. Research priorities for an HIV cure: International AIDS Society global scientific strategy 2021. Nat. Med. 27, 2085–2098 (2021).

    CAS  PubMed  Google Scholar 

  65. Dybul, M. et al. The case for an HIV cure and how to get there. Lancet HIV 8, e51–e58 (2021).

    CAS  PubMed  Google Scholar 

  66. Ho, Y. C. et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155, 540–551 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  67. Siliciano, J. D. et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 9, 727–728 (2003).

    CAS  PubMed  Google Scholar 

  68. Wagner, T. A. et al. HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science 345, 570–573 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  69. Maldarelli, F. et al. HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 345, 179–183 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  70. Einkauf, K. B. et al. Parallel analysis of transcription, integration, and sequence of single HIV-1 proviruses. Cell 185, 266–282.e15 (2022).

    CAS  PubMed  PubMed Central  Google Scholar 

  71. Cohn, L. B. et al. HIV-1 integration landscape during latent and active infection. Cell 160, 420–432 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  72. Nixon, C. C. et al. Systemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivo. Nature 578, 160–165 (2020).

    CAS  PubMed  PubMed Central  Google Scholar 

  73. Badley, A. D., Sainski, A., Wightman, F. & Lewin, S. R. Altering cell death pathways as an approach to cure HIV infection. Cell Death Dis. 4, e718 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  74. Yates, K. B. et al. Epigenetic scars of CD8+ T cell exhaustion persist after cure of chronic infection in humans. Nat. Immunol. 22, 1020–1029 (2021).

    CAS  PubMed  PubMed Central  Google Scholar 

  75. Rutishauser, R. L. et al. TCF-1 regulates HIV-specific CD8+ T cell expansion capacity. JCI Insight 6, e136648 (2021).

    PubMed  PubMed Central  Google Scholar 

  76. Mancuso, P. et al. CRISPR based editing of SIV proviral DNA in ART treated non-human primates. Nat. Commun. 11, 6065 (2020).

    CAS  PubMed  PubMed Central  Google Scholar 

  77. Kessing, C. F. et al. In vivo suppression of HIV rebound by didehydro-cortistatin A, a “block-and-lock” strategy for HIV-1 treatment. Cell Rep. 21, 600–611 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  78. Borducchi, E. N. et al. Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. Nature 540, 284–287 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  79. Bailon, L. et al. Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial. Nat. Med. 28, 2611–2621 (2022).

    CAS  PubMed  Google Scholar 

  80. Nishimura, Y. et al. Early antibody therapy can induce long-lasting immunity to SHIV. Nature 543, 559–563 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  81. Mendoza, P. et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature 561, 479–484 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  82. Borducchi, E. N. et al. Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature 563, 360–364 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  83. Niessl, J. et al. Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity. Nat. Med. 26, 222–227 (2020).

    CAS  PubMed  PubMed Central  Google Scholar 

  84. Gunst, J. D. et al. Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial. Nat. Med. 28, 2424–2435 (2022).

    CAS  PubMed  Google Scholar 

  85. Tebas, P. et al. CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. J. Clin. Invest. 131, e144486 (2021).

    CAS  PubMed  PubMed Central  Google Scholar 

  86. Gardner, M. R. et al. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature 519, 87–91 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  87. Martinez-Navio, J. M. et al. Adeno-associated virus delivery of anti-HIV monoclonal antibodies can drive long-term virologic suppression. Immunity 50, 567–575.e5 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  88. Casazza, J. P. et al. Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial. Nat. Med. 28, 1022–1030 (2022).

    CAS  PubMed  PubMed Central  Google Scholar 

  89. Hutter, G. et al. Long-term control of HIV by CCR5 delta32/delta32 stem-cell transplantation. N. Engl. J. Med. 360, 692–698 (2009).

    PubMed  Google Scholar 

  90. Gupta, R. K. et al. HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation. Nature 568, 244–248 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  91. Okoye, A. A. et al. Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound. Nat. Med. 24, 1430–1440 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  92. Henrich, T. J. et al. HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: an observational study. PLoS Med. 14, e1002417 (2017).

    PubMed  PubMed Central  Google Scholar 

  93. Mitchell, J. L. et al. Plasmacytoid dendritic cells sense HIV replication before detectable viremia following treatment interruption. J. Clin. Invest. 130, 2845–2858 (2020).

    CAS  PubMed  PubMed Central  Google Scholar 

  94. Gondim, M. V. P. et al. Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption. Sci. Transl Med. 13, eabd8179 (2021).

    CAS  PubMed  PubMed Central  Google Scholar 

  95. Prator, C. A. et al. Circulating CD30+CD4+ T cells increase before human immunodeficiency virus rebound after analytical antiretroviral treatment interruption. J. Infect. Dis. 221, 1146–1155 (2020).

    CAS  PubMed  Google Scholar 

  96. Landovitz, R. J. et al. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. Lancet HIV 7, e472–e481 (2020).

    PubMed  PubMed Central  Google Scholar 

  97. Eshleman, S. H. et al. HIV RNA screening reduces integrase strand transfer inhibitor resistance risk in persons receiving long-acting cabotegravir for HIV prevention. J. Infect. Dis. 226, 2170–2180 (2022).

    CAS  PubMed  PubMed Central  Google Scholar 

  98. Beacroft, L. & Hallett, T. B. The potential impact of a “curative intervention” for HIV: a modelling study. Glob. Health Res. Policy 4, 2 (2019).

    PubMed  PubMed Central  Google Scholar 

  99. Lehman, D. A. et al. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis. J. Infect. Dis. 211, 1211–1218 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  100. Dube, K. et al. Participant experiences using novel home-based blood collection device for viral load testing in the HIV cure trials with analytical treatment interruptions. HIV Res. Clin. Pract. 23, 76–90 (2022).

    PubMed  PubMed Central  Google Scholar 

  101. Deeks, S. G. et al. Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1. J. Infect. Dis. 189, 312–321 (2004).

    CAS  PubMed  Google Scholar 

  102. Bertagnolli, L. N. et al. Autologous IgG antibodies block outgrowth of a substantial but variable fraction of viruses in the latent reservoir for HIV-1. Proc. Natl Acad. Sci. USA 117, 32066–32077 (2020).

    CAS  PubMed  PubMed Central  Google Scholar 

  103. Blazkova, J. et al. Distinct mechanisms of long-term virologic control in two HIV-infected individuals after treatment interruption of anti-retroviral therapy. Nat. Med. 27, 1893–1898 (2021).

    CAS  PubMed  Google Scholar 

  104. Jones, R. B. & Walker, B. D. HIV-specific CD8+ T cells and HIV eradication. J. Clin. Invest. 126, 455–463 (2016).

    PubMed  PubMed Central  Google Scholar 

  105. Collins, D. R., Gaiha, G. D. & Walker, B. D. CD8+ T cells in HIV control, cure and prevention. Nat. Rev. Immunol. 20, 471–482 (2020).

    CAS  PubMed  PubMed Central  Google Scholar 

  106. Fukazawa, Y. et al. B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers. Nat. Med. 21, 132–139 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  107. Imamichi, H. et al. Defective HIV-1 proviruses produce viral proteins. Proc. Natl Acad. Sci. USA 117, 3704–3710 (2020).

    CAS  PubMed  PubMed Central  Google Scholar 

  108. Pollack, R. A. et al. Defective HIV-1 proviruses are expressed and can be recognized by cytotoxic T lymphocytes, which shape the proviral landscape. Cell Host Microbe 21, 494–506.e4 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  109. Gaiha, G. D. et al. Structural topology defines protective CD8+ T cell epitopes in the HIV proteome. Science 364, 480–484 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  110. Mothe, B. et al. Therapeutic vaccination refocuses T-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study). eClinicalMedicine 11, 65–80 (2019).

    PubMed  PubMed Central  Google Scholar 

  111. Korber, B. & Fischer, W. T cell-based strategies for HIV-1 vaccines. Hum. Vaccin. Immunother. 16, 713–722 (2020).

    CAS  PubMed  Google Scholar 

  112. Stevenson, E. M. et al. HIV-specific T cell responses reflect substantive in vivo interactions with antigen despite long-term therapy. JCI Insight 6, e142640 (2021).

    PubMed  PubMed Central  Google Scholar 

  113. Stevenson, E. M. et al. SARS CoV-2 mRNA vaccination exposes latent HIV to Nef-specific CD8+ T-cells. Nat. Commun. 13, 4888 (2022).

    CAS  PubMed  PubMed Central  Google Scholar 

  114. Duette, G. et al. The HIV-1 proviral landscape reveals that Nef contributes to HIV-1 persistence in effector memory CD4+ T cells. J. Clin. Invest. 132, e154422 (2022).

    CAS  PubMed  PubMed Central  Google Scholar 

  115. Collins, D. R. et al. Functional impairment of HIV-specific CD8+ T cells precedes aborted spontaneous control of viremia. Immunity 54, 2372–2384.e7 (2021).

    CAS  PubMed  PubMed Central  Google Scholar 

  116. Lewin, S. R. et al. Multi-stakeholder consensus on a target product profile for an HIV cure. Lancet HIV 8, e42–e50 (2021).

    CAS  PubMed  Google Scholar 

  117. Colasanti, J. et al. Continuous retention and viral suppression provide further insights into the HIV care continuum compared to the cross-sectional HIV care cascade. Clin. Infect. Dis. 62, 648–654 (2016).

    PubMed  Google Scholar 

  118. Joint United Nations Programme on HIV/AIDS. African leaders unite in pledge to end AIDS in children. UNAIDS https://www.unaids.org/en/keywords/children (2023).

  119. Patel, P. et al. Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials. HIV Med. 24, 568–579 (2022).

    PubMed  Google Scholar 

  120. Penazzato, M. et al. Advancing the prevention and treatment of HIV in children: priorities for research and development. Lancet HIV 9, e658–e666 (2022).

    CAS  PubMed  Google Scholar 

  121. Persaud, D. et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N. Engl. J. Med. 369, 1828–1835 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  122. Violari, A. et al. A child with perinatal HIV infection and long-term sustained virological control following antiretroviral treatment cessation. Nat. Commun. 10, 412 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  123. Frange, P. et al. HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report. Lancet HIV 3, e49–54 (2016).

    PubMed  Google Scholar 

  124. Hartana, C. A. et al. Immune correlates of HIV-1 reservoir cell decline in early-treated infants. Cell Rep. 40, 111126 (2022).

    CAS  PubMed  PubMed Central  Google Scholar 

  125. Uprety, P. et al. Human immunodeficiency virus type 1 DNA decay dynamics with early, long-term virologic control of perinatal infection. Clin. Infect. Dis. 64, 1471–1478 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  126. Capparelli, E. V. et al. Safety and pharmacokinetics of intravenous 10-1074 and VRC01LS in young children. J. Acquir. Immune Defic. Syndr. 91, 182–188 (2022).

    CAS  PubMed  Google Scholar 

  127. Bonacci, R. A., Smith, D. K. & Ojikutu, B. O. Toward greater pre-exposure prophylaxis equity: increasing provision and uptake for black and Hispanic/Latino individuals in the US. Am. J. Prev. Med. 61, S60–S72 (2021).

    PubMed  PubMed Central  Google Scholar 

  128. Harris, N. S. et al. Vital signs: status of human immunodeficiency virus testing, viral suppression, and HIV preexposure prophylaxis — United States, 2013–2018. MMWR Morb. Mortal. Wkly. Rep. 68, 1117–1123 (2019).

    PubMed  PubMed Central  Google Scholar 

  129. Xavier Hall, C. D., Feinstein, B. A., Rusie, L., Phillips Ii, G. & Beach, L. B. Race and sexual identity differences in PrEP continuum outcomes among Latino men in a large Chicago area healthcare network. AIDS Behav. 26, 1943–1955 (2022).

    PubMed  PubMed Central  Google Scholar 

  130. Monroe, A. K. et al. Integrase inhibitor prescribing disparities in the DC and Johns Hopkins HIV cohorts. Open Forum Infect. Dis. 8, ofab338 (2021).

    PubMed  PubMed Central  Google Scholar 

  131. Joint United Nations Programme on HIV/AIDS. In danger: UNAIDS global AIDS update 2022 (UNAIDS, 2022).

  132. Yukl, S. A. et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin Patient. PLoS Pathog. 9, e1003347 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  133. Jensen, B.-E. O. et al. In-depth virological and immunological characterization of HIV-1 cure after CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation. Nat. Med. 29, 583–587 (2023).

    Google Scholar 

  134. Hsu, J. et al. HIV-1 remission and possible cure in a woman after haplo-cord blood transplant. Cell 186, 1115–1126.e8 (2023).

    CAS  PubMed  Google Scholar 

  135. Mendoza, D. et al. Comprehensive analysis of unique cases with extraordinary control over HIV replication. Blood 119, 4645–4655 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  136. Saez-Cirion, A. et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 9, e1003211 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles, CA, USA

    Raphael J. Landovitz

  2. Bridge HIV, San Francisco Department of Public Health, San Francisco, CA, USA

    Hyman Scott

  3. Division of HIV, Infectious Diseases & Global Medicine, Department of Medicine, University of California, San Francisco, CA, USA

    Hyman Scott & Steven G. Deeks

Authors
  1. Raphael J. Landovitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hyman Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Steven G. Deeks
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

S.G.D. researched data for the article. All authors contributed substantially to discussion of the content. All authors wrote the article. All authors reviewed and/or edited the manuscript before submission.

Corresponding author

Correspondence to Steven G. Deeks.

Ethics declarations

Competing interests

The authors declare no competing interests.

Peer review

Peer review information

Nature Reviews Microbiology thanks Linda-Gail Bekker and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Landovitz, R.J., Scott, H. & Deeks, S.G. Prevention, treatment and cure of HIV infection. Nat Rev Microbiol 21, 657–670 (2023). https://doi.org/10.1038/s41579-023-00914-1

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41579-023-00914-1

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing